Takeda Pharmaceutical, a leading pharmaceutical company, is scheduled to announce its first-quarter financial results on Thursday. Here are the key details you need to know:

Net Profit Forecast

Analysts from S&P Global Market Intelligence predict that Takeda Pharmaceutical will report a 8.1% increase in net profit, reaching ¥113.53 billion ($802.4 million) for the quarter ending June 30. This compares to ¥105.01 billion net profit in the same period last year.

Revenue Forecast

The forecast suggests that Takeda Pharmaceutical's first-quarter revenue is expected to grow by 0.9% year-on-year, reaching ¥981.24 billion, according to the survey conducted by S&P Global.

What to Watch

Key Drugs

Takeda's revenue growth in the fourth quarter was driven by the success of several key drugs. Sales of the ulcerative colitis drug Entyvio grew by 23% to ¥154.9 billion. The sales of Vyvanse, a drug used for attention deficit hyperactivity disorder, soared by 51% to ¥123.8 billion. Additionally, sales of plasma-derived products increased by 22% to ¥176.0 billion. Investors are particularly interested in the sales growth of these crucial drugs.

Debt Burden

Takeda has shown progress in reducing its net-debt-to-adjusted-Ebitda ratio, which decreased from 2.8 to 2.6 between March of last year and March of this year. Investors will be closely monitoring any further improvements in this area.


In May, Takeda projected a 4.7% decline in revenue to ¥3.840 trillion and a 55% drop in net profit to ¥142.0 billion for the fiscal year ending in March 2024. Investors will be paying close attention to any updates or changes to the annual guidance provided by the management.

Post a comment